Development of an Antiepileptogenesis Drug Screening Platform: Effects of Everolimus and Phenobarbital
暂无分享,去创建一个
K. Wilcox | M. Barker-Haliski | H. White | Cameron S. Metcalf | Dannielle K. Zierath | Zachery Koneval | Kevin M. Knox | H. Steve White | H. S. White
[1] M. Barker-Haliski,et al. Diurnal burden of spontaneous seizures in early epileptogenesis in the post‐kainic acid rat model of epilepsy , 2021, Epilepsia open.
[2] D. Fabbro,et al. Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex , 2020, Neuropharmacology.
[3] K. Thomson,et al. Evaluation of subchronic administration of antiseizure drugs in spontaneously seizing rats , 2020, Epilepsia.
[4] M. Barker-Haliski,et al. Validated animal models for antiseizure drug (ASD) discovery: Advantages and potential pitfalls in ASD screening , 2020, Neuropharmacology.
[5] F. Jansen,et al. Update on Drug Management of Refractory Epilepsy in Tuberous Sclerosis Complex , 2020, Pediatric Drugs.
[6] P. Crino. Mechanistic target of rapamycin (mTOR) signaling in status epilepticus , 2019, Epilepsy & Behavior.
[7] D. Franz,et al. Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures , 2019, Expert review of neurotherapeutics.
[8] F. Dudek,et al. Effect of carbamazepine on spontaneous recurrent seizures recorded from the dentate gyrus in rats with kainate‐induced epilepsy , 2019, Epilepsia.
[9] E. Aronica,et al. mTOR dysregulation and tuberous sclerosis-related epilepsy , 2018, Expert review of neurotherapeutics.
[10] M. Wong,et al. Targeting the Mammalian Target of Rapamycin for Epileptic Encephalopathies and Malformations of Cortical Development , 2018, Journal of child neurology.
[11] S. Dedeurwaerdere,et al. Kainic Acid-Induced Post-Status Epilepticus Models of Temporal Lobe Epilepsy with Diverging Seizure Phenotype and Neuropathology , 2017, Front. Neurol..
[12] J. Kehne,et al. The National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP) , 2017, Neurochemical Research.
[13] Roy M. Smeal,et al. Hippocampal TNFα Signaling Contributes to Seizure Generation in an Infection-Induced Mouse Model of Limbic Epilepsy , 2017, eNeuro.
[14] Yi-Chin Lin,et al. Everolimus is better than rapamycin in attenuating neuroinflammation in kainic acid-induced seizures , 2017, Journal of Neuroinflammation.
[15] T. H. Sasongko,et al. Rapamycin and rapalogs for tuberous sclerosis complex. , 2016, The Cochrane database of systematic reviews.
[16] Lars E. Borm,et al. Effects of rapamycin and curcumin treatment on the development of epilepsy after electrically induced status epilepticus in rats , 2016, Epilepsia.
[17] E. Thiele,et al. Tuberous Sclerosis Complex , 2019, Harper's Textbook of Pediatric Dermatology.
[18] S. Jóźwiak,et al. Role of mTOR inhibitors in epilepsy treatment , 2015, Pharmacological reports : PR.
[19] J. French,et al. Disease Modification in Epilepsy: From Animal Models to Clinical Applications , 2015, Drugs.
[20] Kyle E. Thomson,et al. A novel open-source drug-delivery system that allows for first-of-kind simulation of nonadherence to pharmacological interventions in animal disease models , 2014, Journal of Neuroscience Methods.
[21] D. Friedman,et al. How Clinical Development Can, and Should, Inform Translational Science , 2014, Neuron.
[22] Francesco Brigo,et al. Antiepileptogenesis in humans: disappointing clinical evidence and ways to move forward. , 2014, Current opinion in neurology.
[23] W. Löscher,et al. Searching for the Ideal Antiepileptogenic Agent in Experimental Models: Single Treatment Versus Combinatorial Treatment Strategies , 2014, Neurotherapeutics.
[24] K. Thomson,et al. The expression of kainate receptor subunits in hippocampal astrocytes after experimentally induced status epilepticus. , 2013, Journal of neuropathology and experimental neurology.
[25] I. Módy,et al. Issues related to development of antiepileptogenic therapies , 2013, Epilepsia.
[26] D. Brody,et al. Rapamycin Attenuates the Development of Posttraumatic Epilepsy in a Mouse Model of Traumatic Brain Injury , 2013, PloS one.
[27] T. Grandin,et al. AVMA Guidelines for the Euthanasia of Animals: 2013 Edition , 2013 .
[28] J. McMahon,et al. Rapamycin attenuates aggressive behavior in a rat model of pilocarpine-induced epilepsy , 2012, Neuroscience.
[29] G. Brophy,et al. Practice Variations in the Management of Status Epilepticus , 2012, Neurocritical Care.
[30] S. Koh,et al. Minocycline attenuates microglia activation and blocks the long-term epileptogenic effects of early-life seizures , 2012, Neurobiology of Disease.
[31] Paul M. Vespa,et al. Guidelines for the Evaluation and Management of Status Epilepticus , 2012, Neurocritical Care.
[32] K. Lukasiuk,et al. Post-treatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy , 2012, Neuroscience Letters.
[33] N. Temkin,et al. Antiepileptogenic Agents How Close Are We ? , 2012 .
[34] A. Robertson,et al. Domoic acid and human exposure risks: a review. , 2010, Toxicon : official journal of the International Society on Toxinology.
[35] M. Wong. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies , 2010, Epilepsia.
[36] L. Zeng,et al. The Mammalian Target of Rapamycin Signaling Pathway Mediates Epileptogenesis in a Model of Temporal Lobe Epilepsy , 2009, The Journal of Neuroscience.
[37] N. Temkin. Preventing and treating posttraumatic seizures: The human experience , 2009, Epilepsia.
[38] W. Löscher. The Pharmacokinetics of Antiepileptic Drugs in Rats: Consequences for Maintaining Effective Drug Levels during Prolonged Drug Administration in Rat Models of Epilepsy , 2007, Epilepsia.
[39] L. Murri,et al. Phenobarbital prophylaxis of post traumatic epilepsy , 1979, Neurological Sciences.
[40] Philip A. Williams,et al. Use of Chronic Epilepsy Models in Antiepileptic Drug Discovery: The Effect of Topiramate on Spontaneous Motor Seizures in Rats with Kainate‐induced Epilepsy , 2005, Epilepsia.
[41] L. Murri,et al. Phenobarbital in the prophylaxis of late posttraumatic seizures , 1992, The Italian Journal of Neurological Sciences.
[42] E. Cavalheiro,et al. New insights from the use of pilocarpine and kainate models , 2002, Epilepsy Research.
[43] E. Bertram,et al. Phenobarbital and MK‐801, but not phenytoin, improve the long‐term outcome of status epilepticus , 2002, Annals of neurology.
[44] N. Temkin. Antiepileptogenesis and Seizure Prevention Trials with Antiepileptic Drugs: Meta‐Analysis of Controlled Trials , 2001, Epilepsia.
[45] N R Temkin,et al. Antiepileptogenic agents: how close are we? , 2001, Drugs.
[46] Y. Ben-Ari,et al. Kainate, a double agent that generates seizures: two decades of progress , 2000, Trends in Neurosciences.
[47] G. Holmes,et al. Comparison of valproate and phenobarbital treatment after status epilepticus in rats , 1998, Neurology.
[48] F. Edward Dudek,et al. Recurrent spontaneous motor seizures after repeated low-dose systemic treatment with kainate: assessment of a rat model of temporal lobe epilepsy , 1998, Epilepsy Research.
[49] W. Hauser,et al. A population-based study of seizures after traumatic brain injuries. , 1998, The New England journal of medicine.
[50] G. Holmes,et al. Age‐Dependent Cognitive and Behavioral Deficits After Kainic Acid Seizures , 1993, Epilepsia.
[51] G. Golarai,et al. Alteration of long-lasting structural and functional effects of kainic acid in the hippocampus by brief treatment with phenobarbital , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[52] W. Hauser,et al. Prevalence of Epilepsy in Rochester, Minnesota: 1940–1980 , 1991, Epilepsia.